Deleterious effects of selective serotonin reuptake inhibitor treatment on semen parameters in patients with lifelong premature ejaculation

International Journal of Impotence Research

Volumn 24, Issue 5, 2012, Pages 171-173

  Koyuncu, H ^a   Serefoglu, E C ^b   Ozdemir, A T ^c   Hellstrom, W J ^b  

^a YEDITEPE UNIVERSITY   (Turkey)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

adverse effects; premature ejaculation; selective serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANORGASMIA; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; EJACULATION; EJACULATION DISORDER; FATIGUE; HUMAN; LATENT PERIOD; LIBIDO DISORDER; MALE FERTILITY; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PREMATURE EJACULATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEROTONIN RELEASE; SEXUAL DYSFUNCTION; SPERM; SPERMATOZOON MIGRATION; VOMITING; XEROSTOMIA;

CELL SURVIVAL; DNA; HUMANS; INFERTILITY, MALE; MALE; PREMATURE EJACULATION; SEMEN; SEROTONIN UPTAKE INHIBITORS; SPERM MOTILITY; SPERMATOGENESIS; SPERMATOZOA;

EID: 84866384831     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2012.12     Document Type: Review

References (37)

1. American Psychiatric Association. Diagnostic criteria from DSM-IV-TR. American Psychiatric Association: Washington, DC, 2000.
2. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: Prevalence, comorbidites, and professional help-seeking. Eur Urol 2007; 51: 816-824.
3. Read S, King M, Watson J. Sexual dysfunction in primary medical care: Prevalence, characteristics and detection by the general practitioner. J Public Health Med 1997; 19: 387-391.
4. Giuliano F, Patrick DL, Porst H. Premature ejaculation: Results from a five country European observational study. Eur Urol 2008; 53: 1048-1057.
5. Sotomayor M. The burden of premature ejaculation: The patient's perspective. J Sex Med 2005; 2: 110-114.
6. Symonds T, Roblin D, Hart K, Althof S. How does premature ejaculation impact a man's life? J Sex Mar Ther 2003; 29: 361-370.
7. Godpodinoff ML. Premature ejaculation: Clinical subgroups and etiology. J Sex Marital Ther 1989; 15: 130-134.
8. McMahon CG, Althof S, Waldinger MD, Porst H, Dean J, Sharlip I et al. An evidencebased definition of lifelong premature ejaculation: Report of the International Society for Sexual Medicine ad hoc committee for the definition of premature ejaculation. J Sex Med 2008; 5: 1590-1606.
9. Giuliano F, Clement P. Serotonin and premature ejaculation: From physiology to patient management. Eur Urol 2006; 50: 454-466.
10. Wespes E, Amar E, Eardly I, Giuliano F, Hatzichristou D, Hatzimouratidis K et al. Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation. European Association of Urology Guidelines, Drukkerij Gelderlandbv. Arnhem-Netherlands 2011; 31-46.
11. Safarinejad MR. Sperm DNA damage and semen quality impairment after treatment with selective serotonin reuptake inhibitors detected using semen analysis and sperm chromatin structure assay. J Urol 2008; 180: 2124-2128.
12. Tanrikut C, Feldman AS, Altemus M, Paduch DA, Schlegel PN. Adverse effect of paroxetine on sperm. Fertil Steril 2010; 94: 1021-1026.
13. Koyuncu HH, Serefoglu EC, Yencilek E, Atalay H, Akbas N, Sarica K. Escitalopram treatment for premature ejaculation has a negative effect on semen parameters. Int J Impot Res 2011; 23: 257-261.
14. Arafa M, Shamloul R. A randomized study examining the effect of 3 SSRI on premature ejaculation using a validated questionnaire. Ther Clin Risk Manag 2007; 3: 527-531.
15. Safarinejad RM. Safety and efficacy of escitalopram in the treatment of premature ejaculation: A double-blind placebo-controlled, fixed dose, randomized study. J Clin Psychopharmacol 2007; 27: 444-450.
16. Waldinger MD, Zwinderman AH, Schweitzer DH. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: A systematic review and meta-analysis. Int J Impot Res 2004; 16: 369-381.
17. Waldinger MD, Van De Plas A, Pattij T, Van Oorschot R, Coolen LM, Veening JG et al. The selective serotonin re-uptake inhibitors fluvoxamine and paroxetine differ in sexual inhibitory effects after chronic treatment. Psychopharmacology 2002; 160: 283-289.
18. Waldinger MD, Berendsen HH, Blok BF, Olivier, Holstege G. Premature ejaculation and SSRI-induced delayed ejaculation: The involvement of the serotonergic system. Behav Brain Res 1998; 92: 111-118.
19. Waldinger MD, Olivier B. Selective serotonin reuptake inhibitor-induced sexual dysfunction: Clinical and research considerations. Int Clin Psychopharmacol 1998; 13: 27-33.
20. Hellstrom WJG. Emerging treatments for premature ejaculation: Focus on dapoxetine. Neuropsychiatr Dis Treat 2009; 5: 37-46.
21. Wylie KR, Ralph D. Premature ejaculation: The current literature. Curr Opin Urol 2005; 15: 393-398.
22. Sadeghi-Nejad H, Watson W. Premature ejaculation: Current medical treatment and new directions. J Sex Med 2008; 5: 1037-1050.
23. Waldinger MD. Premature ejaculation: Definition and drug treatment. Drugs 2007; 67: 547-568.
24. Montejo AL, Llorca G, Izquierdo JA, Rico-Willademoros F. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psycholotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62: 10-21.
25. Wolf WA, Kuhn DM. Role of essential sulfhdryl groups in drug interactions at the neuronal 5-HT transporter. Differences between amphetamines and 5-HT uptake inhibitors. J Biol Chem 1992; 267: 20820-20825.
26. De Lamirande E, Gagnon C. Paradoxical effect of reagents for sulfhydryl and disulfide groups on human sperm capacitation and superoxide production. Free Radic Biol Med 1998; 257: 803-817.
27. De Lamirande E, Gagnon C. Redox control of changes in protein sulfhydryl levels during human sperm capacitation. Free Radic Biol Med 2003; 35: 1271-1285.
28. Kumar K, Sharma LV, Tiwari P, Singh D, Maikhuri JP, Gupta G et al. The spermicidal and antitrichomonas activities of SSRI antidepressants. Bioorg Med Chem Lett 2006; 16: 2509-2512.
29. Tanrikut C, Schegel PN. Antidepressant-associated changes in semen parameters. Urology 2007; 69: 185-187.
30. Evenson DP, Jost LK, Marshall D, Zinaman MJ, Clegg E, Purvis K. Utility of the sperm chromatin structure assay as diagnostic and prognostic tool in the human fertility clinic. Hum Reprod 1999; 14: 1039-1049.
31. Irvine DS, Twigg JP, Gordon EL, Fulton N, Milne PA, Aitken RJ. DNA integrity in human spermatozoa: Relationships with semen quality. J Androl 2000; 21: 33-44.
32. Spano M, Bonde JP, Hjollund HI, Kolstad HA, Cordelli E, Leter G. Sperm chromatin damage impairs human fertility. The Danish First Pregnancy Planner Study Team. Fertil Steril 2000; 73: 43-50.
33. Lopes S, Sun JG, Jurisicova A, Meriano J, Casper RF. Sperm deoxyribonucleic acid fragmentation is increased in poor-quality semen samples and correlates with failed fertilization in intracytoplasmic sperm injection. Fertil Steril 1998; 69: 528-532.
34. Tanaka E, Baba N, Toshida K, Suzuki K. Evidence for 5HT2 receptor involvement in the stimulation of preovulatory LH and prolactin release and ovulation in normal cycling rats. Life Sci 1993; 52: 669-676.
35. Meltzer H, Bastani B, Jayathilake K, Maes M. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Neuropsychopharmacology 1997; 17: 1.
36. World Health Organization. WHO Manual for the Standardised Investigation and Diagnosis of the Infertile Couple. Cambridge: Cambridge University Press, 2000.
37. Nieschlag E, Behre HM (eds) Andrology: Male Reproductive Health and Dysfunction, 2nd edn. Springer Verlag: Berlin, chapter 5, 2009 p 83-87.